For professionals in the cannabis industry

Spannabis: a celebration of the cannabis sector despite lingering uncertainties

Written by Tiziana Cauli | 14th March 2023

Business representatives and scientists from across the globe gathered in Barcelona last week for a series of international events dedicated to the world of legal cannabis ...

Oklahoma voters show the path to legal recreational cannabis isn’t always easy

Written by Freddie Dawson | 8th March 2023

The march to recreational cannabis legalisation in the US is by no means a straight line upwards, as the recent ballot result in Oklahoma shows ...

Tamarind Intelligence – analysis and data trusted by governments and beyond

Written by CannIntelligence | 2nd March 2023

Tamarind Intelligence data continues to be an invaluable tool used by governments and NGOs around the world, contributing to a wide number of government and supra-national projects ...

Another poll finds huge popular support for US legalisation – but who is listening?

Written by Freddie Dawson | 16th February 2023

Another poll weighted to be nationally representative of US voters has shown strong support for legalising adult use of recreational cannabis – and broad backing for including social equity measures ...

Could a smart rapper help smokable hemp seriously disrupt Big Tobacco?

Written by Freddie Dawson | 9th February 2023

Could the involvement of Snoop Dogg help a Californian companyt to “disrupt tobacco’s nearly $1tn industry with hemp cigarettes, smoking paper and other alternatives to nicotine tobacco”? ...

If teenage cannabis use is rising, that has nothing to do with adult legalisation

Written by CannIntelligence | 2nd February 2023

While youth cannabis use is increasing in the US, contextual data show this trend is not associated with the creation of legal cannabis markets ...

How did we do? CannIntelligence’s 2022 predictions measured against events

Written by Freddie Dawson | 18th January 2023

CannIntelligence predicted that 2022 would be the year of intoxicating hemp-derived cannabinoids (IHDCs) and that has proven to be the case. But’s not been plain sailing for cannabis or CBD ...

Much-needed research into SCRAs’ huge medical potential faces high barriers

Written by Freddie Dawson | 12th January 2023

The recreational reputation of synthetic cannabinoids – synthetic cannabinoid receptor agonists (SCRAs) – precedes them, leading to restrictions on use and even research ...

Of headaches, pirates and the rise in cannabis against tobacco smoking

Written by Aidan Semmens | 5th January 2023

Correlation is not causation, but it’s tempting to see a meaningful pattern in figures showing that US adults (particularly the younger ones) are smoking less tobacco and using more cannabis ...

Pain, pot and placebos – flawed study fails to reveal their true relationship

Written by CannIntelligence | 22nd December 2022

Despite what its authors claim, a new and widely reported study fails to establish that the analgesic properties of cannabis can be largely attributable to the placebo effect ...

Cannabis and dopamine – potential good news for bipolar disorder sufferers

Written by CannIntelligence | 13th December 2022

New research suggests that the effect of cannabis on dopamine may help to treat certain symptoms of bipolar disorder, with a reduced tendency to engage in risky behaviours and some improvement in cognitive ability ...

Simon the brand-builder demonstrates confidence in future of cannabis drinks

Written by Lorraine Mullaney | 7th December 2022

Cannabis-infused drinks have been the subject of industry debate and speculation as they raise many challenges – from regulatory hurdles to dosage issues and taste formulation – but is it just a case of "when",...

Re-election of Florida governor DeSantis could hit Green Thumb’s Circle K deal

Written by CannIntelligence | 24th November 2022

The re-election of Florida’s Republican governor Ron DeSantis raises doubts over a deal between the convenience and fuel retailer Circle-K and Green Thumb Industries to roll out a series of small medical cannabis dispensaries ...

How will the EU’s proposed new rules on batteries affect cannabinoid vapes?

Written by Dmytro Korchahin | 17th November 2022

The upcoming revision of the regulation of batteries in the EU may well have a profound effect the industry, with safety, sustainability and the environment all coming under the lawmakers' microscope ...

CannIntelligence meets the stars at the World CBD awards in Barcelona

Written by Tiziana Cauli | 16th November 2022

CannIntelligence was among the participants at the recent World CBD Awards show in Barcelona. Check out our red carpet video for a fuller flavour of what happened on the night ...

Bullish GVB Biopharma bucks the US trend for falling hemp production

Written by Freddie Dawson | 10th November 2022

News from 22nd Century Group provides an interesting contrast to the current US trend for falling hemp acreagres and cutbacks ...

How far will Biden and state governors go on pardons for cannabis offenders?

Written by Freddie Dawson | 3rd November 2022

It looks like at least two state governors have taken up US president Joe Biden’s urging of them to back up his recent pardon of all non-violent cannabis possession offences ...

What is attracting the American right to put cash and effort behind psychedelics?

Written by Freddie Dawson | 19th October 2022

It is not only cannabis that is attracting what might be thought unexpected investment and support from traditionally conservative, right-wing supporters and lobbyists in the US ...

Vaping and weed – gateway to confusion between correlation and causation

Written by CannIntelligence | 13th October 2022

Another study has confused correlation and causation when it comes to youth vaping and the supposed gateway effect – this time linking vaping and later cannabis use ...

Cannabis may help against opioids – but this latest study doesn’t tell us much

Written by CannIntelligence | 6th October 2022

Reducing opioid dependence is a primary goal of medical cannabis programmes, but there remains a need for rigorous science when making decisions about the interaction between cannabis and opioid use for pain ...

Opposite sides attract, as Navajo oppose any bid to decriminalise use of peyote

Written by Freddie Dawson | 22nd September 2022

Drug legalisation as an issue truly does bring together some strange bedfellows – like the Navajo Nation and drug prohibitionists ...

How will open access to federally funded research affect US cannabis science?

Written by CannIntelligence | 14th September 2022

The Biden Administration recently released a memorandum requiring research receiving federal funds to be made available to the public without charge. But what effect will this have on cannabis research? ...

Coming together over cannabis: is support becoming a bipartisan issue?

Written by Freddie Dawson | 8th September 2022

Once mainly the purview of fringe leftists, support for cannabis continues to become more of a bipartisan issue ...

Could cannabis help improve outcomes for patients badly afflicted by Covid?

Written by CannIntelligence | 18th August 2022

A study published this month provides further evidence that cannabis could be helpful in treating severe late-stage Covid-19 ...

Trouble in Lima – hemp bill’s chances tied up in Peru’s congressional crisis

Written by Freddie Dawson | 10th August 2022

New legislation has been put forward in Peru to establish a framework for the production and commercialisation of hemp – but what are its chances of passing in a period of political turmoil? ...

In a world of wide-boys and no-hopers, who should have a licence to sell weed?

Written by Freddie Dawson | 4th August 2022

It’s difficult to get a licence to operate in the cannabis field in the US if you’ve been convicted of selling cannabis before it was legal. Yet such restrictions do little to protect the market...

Are psychedelics set to follow cannabis into mainstream medical acceptance?

Written by Lorraine Mullaney | 21st July 2022

Psychedelics are having another moment in the spotlight. But is the heightened awareness just hype, or have these once-taboo substances been permanently rehabilitated? ...

Cannabis or marijuana? Why it matters what name you (and the law) know it by

Written by Freddie Dawson | 13th July 2022

There is quite a bit of baggage in how reference is made to the Cannabis sativa plant – as demonstrated by what's behind a new change to the law in the US state of Washington...

No magic solution: EFSA ingestible CBD safety concerns won’t be resolved quickly

Written by Freddie Dawson | 1st July 2022

It looks like there will be no easy or quick solutions to addressing the data gaps the European Food Safety Authority (EFSA) requires to reach a conclusion on the safety of CBD as an ingestible...

Why the long pause? Companies question Efsa’s insistence on filling ‘data gap’

Written by Freddie Dawson | 23rd June 2022

In trying to be overly cautious on novel foods, has the European Food Safety Authority inadvertently added an extra risk to public health? ...

Lack of quality science on cannabis and pain leaves room for fake news and myth

Written by Barnaby Page | 16th June 2022

“It’s a myth that cannabis relieves pain,” declared the Daily Mail. But that is not what the study it was reporting said at all ...

Can a California cannabis cultivation tax cut help some without harming others?

Written by Freddie Dawson | 9th June 2022

Could lowering taxes lead to more revenue? It’s a question that can be applied to many retail areas, from train tickets to electronics ...

Off the hook – research reveals youth health benefits of legalising cannabis

Written by Aidan Semmens | 31st May 2022

A six-year study of young adult behaviour reveals that when and where cannabis use is legalised, young people’s use of alcoho. and tobacco drops – and so does the use, and misuse, of pain-relieving prescription...

What action in the name of sustainability is the CBD industry likely to see?

Written by Freddie Dawson | 19th May 2022

CBD is already working from a higher base than many consumer products on the market. But that does not mean there is nothing else to be done ...

How likely is it that the US will see further delta-8 THC enforcement?

Written by Freddie Dawson | 12th May 2022

The US Food and Drug Administration (FDA) recently sent its first round of letters concerning delta-8 THC to five companies. How likely is it that the US will see further delta-8 THC enforcement? ...

UK FSA updates novel food list – but what difference will it make to the market?

Written by Freddie Dawson | 5th May 2022

The recent update to the UK Food Standards Agency (FSA)’s list of CBD products linked to validated novel food applications has created further issues and questions in the industry – such as, what will actually...

The common sense of CBD science, and why it doesn’t always come to the fore

Written by Barnaby Page | 21st April 2022

Is the current system of peer-reviewed journal publication the best way to get the best science on CBD and cannabis? There could be another way ...

Polish court decision on hemp as novel food could have big ramifications

Written by Freddie Dawson | 14th April 2022

A Polish appeals court has put forward a decision that may be out of kilter with many other interpretations of the status of hemp as a novel food ...

Will Canadian government’s proposal put renewed fizz in cannabinoid drinks?

Written by Lorraine Mullaney | 6th April 2022

Is the Canadian government’s proposal to increase the number of cannabis-infused drinks that can be legally purchased at one time good news for firms that have invested in cannabinoid-infused beverages? ...

Are there lessons for cannabinoids from the new synthetic-nicotine regulation?

Written by Freddie Dawson | 24th March 2022

Could the cannabinoid industry learn anything from the recent move to close the loophole that had kept synthetic nicotine out of US Food and Drug Administration oversight? ...

Another sign of mainstream acceptance as Amazon gets on board with CBD in US

Written by Freddie Dawson | 21st March 2022

Interest from major players in traditional retail channels continues to grow ...

Is investing in cannabis in 2022 a smart bet or a ‘dead-money scenario’?

Written by Lorraine Mullaney | 9th March 2022

Last month CBD-Intel reported that the Dermapharm Holding bought Canopy Growth’s Cannabinoid Compound Company (C3) for €80m, a huge loss for Canopy, and one of the biggest cannabis acquisitions in Europe at the time. But what makes...

NORML releases delta-8 THC info that’s both misleading and potentially divisive

Written by Freddie Dawson | 3rd March 2022

One of the most prestigious cannabis legalisation lobbying groups has come out with a disappointing – but not surprising – strong line against hemp-derived delta-8 THC products ...

The changing face of endorsements as they get more mainstream – and whiter

Written by CannIntelligence | 17th February 2022

What was once the purview of more “controversial” or “alternative” names has now become the territory of mainstream celebrities designed to appeal to a wider – and whiter – audience ...

Only in California: the fresh vape that’s cannabis and nothing but the cannabis

Written by Aidan Semmens | 9th February 2022

The latest offering from the company that first devised the Juul e-cigarette looks sure to be a new Californian craze – a new vaping pod “made solely from pure cannabis” ...

Will UK FSA at last publish an updated list of validated novel food applications?

Written by Freddie Dawson | 2nd February 2022

Don't hold your breath, but rumours are swirling that the UK Food Standards Agency (FSA) will soon publish an updated, completed list of CBD novel food applications that have been fully validated ...

Despite industry investment, the future remains cloudy for cannabinoid drinks

Written by Lorraine Mullaney | 20th January 2022

Covid has significantly increased consumer interest in health and wellness, with food and drink formulations that create innovative solutions for “mental and emotional wellbeing” becoming a 2021 trend ...

How US Democrats’ cannabis reform plans ran aground despite promises

Written by Lorraine Mullaney | 12th January 2022

After early promise, no cannabis-focused legislation has yet made it onto president Joe Biden’s desk for signing. So why is that? ...

Colombian insurance policy shows real intent to lead on cannabinoids

Written by Freddie Dawson | 6th January 2022

Colombia has joined a select few countries now demanding mandatory coverage of medical cannabis by health insurance providers ...

Legal eagle Kight explains how the USPS could have modified PACT Act regulation

Written by CannIntelligence | 22nd December 2021

Does the United States Postal Service (USPS) really have the authority to permit the shipping of CBD vaping products under the PACT Act? ...

LATEST ALERTS